<DOC>
	<DOCNO>NCT02905799</DOCNO>
	<brief_summary>The purpose study determine whether resveratrol effective treatment painful knee osteoarthritis .</brief_summary>
	<brief_title>Resveratrol Knee Osteoarthritis</brief_title>
	<detailed_description>Osteoarthritis ( OA ) first cause handicap individual 40 years-old France . OA physiopathology driven local joint inflammation responsible pain joint destruction . Experimental study show resveratrol , molecule antagonist aryl hydrocarbon receptor , anti-inflammatory chondroprotective property vitro vivo . The investigator hypothesize resveratrol , new formulation develop coordinate investigator improve bioavailability , decrease pain patient present primary knee OA .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Age ≥ 40 yearsold Knee osteoarthritis fulfil 1986 ACR criterion Pain numeric rating scale ≥ 40/100 Symptom duration ≥ 1 month 4 &gt; Kellgren Lawrence XRay score ≥ 2 No change treatment past month Written consent obtain Health insurance cover History symptomatic crystal inﬂammatory arthritis Knee surgery ≤ 1 year Knee trauma ≤ 2 month Knee intraarticular injection ≤ 2 month Neurologic disorder involve low limb Inability speak write French Participation another biomedical research Contraindication resveratrol hypersensitivity constituent</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Resveratrol</keyword>
	<keyword>Oral Treatment</keyword>
	<keyword>Pain</keyword>
	<keyword>Trial</keyword>
</DOC>